Update on inflammatory bowel disease in patients with primary sclerosing cholangitis

World Journal of Hepatology

Volumn 6, Issue 4, 2014, Pages 178-187

  Tsaitas, Christos ^a   Semertzidou, Anysia ^a   Sinakos, Emmanouil ^a  

^a General Hospital of Thessaloniki   (Greece)

Author keywords

Crohn's disease; Inflammatory bowel disease; Primary sclerosing cholangitis; Ulcerative colitis

Indexed keywords

EID: 84901196466     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i4.178     Document Type: Review

References (115)

1. Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980; 79: 200-206 [PMID: 7399227]
2. Thompson HH, Pitt HA, Tompkins RK, Longmire WP. Primary sclerosing cholangitis: a heterogenous disease. Ann Surg 1982; 196: 127-136 [PMID: 7092362 DOI: 10.1097/000006 58-198208000-00003]
3. Schwartz SI, Dale WA. Primary sclerosing cholangitis; review and report of six cases. AMA Arch Surg 1958; 77: 439-451 [PMID: 13572239 DOI: 10.1001/archsurg.1958.01290030139016]
4. Olsson R, Danielsson A, Järnerot G, Lindström E, Lööf L, Rolny P, Rydén BO, Tysk C, Wallerstedt S. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100: 1319-1323 [PMID: 2013375]
5. Atkinson AJ, Carroll WW. Sclerosing cholangitis. association with regional enteritis. JAMA 1964; 188: 183-184 [PMID: 14107248 DOI: 10.1001/jama.1964.03060280085023]
6. Smith MP, Loe RH. Sclerosing cholangitis; review of recent case reports and associated diseases and four new cases. Am J Surg 1965; 110: 239-246 [PMID: 14313190 DOI: 10.1016/0002 -9610(65)90018-8]
7. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332: 924-933 [PMID: 7877651 DOI: 10.1056/ NEJM199504063321406]
8. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 31-39 [PMID: 2047887 DOI: 10.1055/ s-2008-1040420]
9. Chapman RW, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer PJ, Sherlock S. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21: 870-877 [PMID: 7439807 DOI: 10.1136/gut.21.10.870]
10. Loftus EV, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, Jewell DA, Sandborn WJ. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-96 [PMID: 15591511 DOI: 10.1136/gut.2004.046615]
11. Aadland E, Schrumpf E, Fausa O, Elgjo K, Heilo A, Aakhus T, Gjone E. Primary sclerosing cholangitis: a long-term followup study. Scand J Gastroenterol 1987; 22: 655-664 [PMID: 3659828 DOI: 10.3109/00365528709011139]
12. Verdonk RC, Dijkstra G, Haagsma EB, Shostrom VK, Van den Berg AP, Kleibeuker JH, Langnas AN, Sudan DL. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant 2006; 6: 1422-1429 [PMID: 16686766 DOI: 10.1111/ j.1600-6143.2006.01333.x]
13. Sinakos E, Samuel S, Enders F, Loftus EV, Sandborn WJ, Lindor KD. Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis 2013; 19: 1004-1009 [PMID: 23502353 DOI: 10.1097/ MIB.0b013e3182802893]
14. Bergquist A, Lindberg G, Saarinen S, Broomé U. Increased prevalence of primary sclerosing cholangitis among firstdegree relatives. J Hepatol 2005; 42: 252-256 [PMID: 15664252 DOI: 10.1016/j.jhep.2004.10.011]
15. Bergquist A, Montgomery SM, Bahmanyar S, Olsson R, Danielsson A, Lindgren S, Prytz H, Hultcrantz R, Lööf LA, Sandberg-Gertzén H, Almer S, Askling J, Ehlin A, Ekbom A. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008; 6: 939-943 [PMID: 18674735 DOI: 10.1016/j.cgh.2008.03.016]
16. Donaldson PT. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut 2004; 53: 599-608 [PMID: 15016758 DOI: 10.1136/gut.2003.031732]
17. Moloney MM, Thomson LJ, Strettell MJ, Williams R, Donaldson PT. Human leukocyte antigen-C genes and susceptibility to primary sclerosing cholangitis. Hepatology 1998; 28: 660-662 [PMID: 9731555 DOI: 10.1002/hep.510280309]
18. Norris S, Kondeatis E, Collins R, Satsangi J, Clare M, Chapman R, Stephens H, Harrison P, Vaughan R, Donaldson P. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology 2001; 120: 1475-1482 [PMID: 11313318 DOI: 10.1053/gast.2001.24041]
19. Wiencke K, Spurkland A, Schrumpf E, Boberg KM. Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICA and MICB alleles. Hepatology 2001; 34: 625-630 [PMID: 11584356 DOI: 10.1053/ jhep.2001.27543]
20. Mitchell SA, Grove J, Spurkland A, Boberg KM, Fleming KA, Day CP, Schrumpf E, Chapman RW. Association of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut 2001; 49: 288-294 [PMID: 11454808 DOI: 10.1136/gut.49.2.288]
21. Spurkland A, Saarinen S, Boberg KM, Mitchell S, Broome U, Caballeria L, Ciusani E, Chapman R, Ercilla G, Fausa O, Knutsen I, Pares A, Rosina F, Olerup O, Thorsby E, Schrumpf E. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 1999; 53: 459-469 [PMID: 10372541 DOI: 10.1034/ j.1399-0039.1999.530502.x]
22. Folseraas T, Melum E, Rausch P, Juran BD, Ellinghaus E, Shiryaev A, Laerdahl JK, Ellinghaus D, Schramm C, Weismüller TJ, Gotthardt DN, Hov JR, Clausen OP, Weersma RK, Janse M, Boberg KM, Björnsson E, Marschall HU, Cleynen I, Rosenstiel P, Holm K, Teufel A, Rust C, Gieger C, Wichmann HE, Bergquist A, Ryu E, Ponsioen CY, Runz H, Sterneck M, Vermeire S, Beuers U, Wijmenga C, Schrumpf E, Manns MP, Lazaridis KN, Schreiber S, Baines JF, Franke A, Karlsen TH. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol 2012; 57: 366-375 [PMID: 22521342 DOI: 10.1016/j.jhep.2012.03.031]
23. Karlsen TH, Boberg KM, Vatn M, Bergquist A, Hampe J, Schrumpf E, Thorsby E, Schreiber S, Lie BA. Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis. Genes Immun 2007; 8: 275-278 [PMID: 17301827 DOI: 10.1038/sj.gene.6364377]
24. Janse M, Lamberts LE, Franke L, Raychaudhuri S, Ellinghaus E, Muri Boberg K, Melum E, Folseraas T, Schrumpf E, Bergquist A, Björnsson E, Fu J, Jan Westra H, Groen HJ, Fehrmann RS, Smolonska J, van den Berg LH, Ophoff RA, Porte RJ, Weismüller TJ, Wedemeyer J, Schramm C, Sterneck M, Günther R, Braun F, Vermeire S, Henckaerts L, Wijmenga C, Ponsioen CY, Schreiber S, Karlsen TH, Franke A, Weersma RK. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology 2011; 53: 1977-1985 [PMID: 21425313 DOI: 10.1002/hep.24307]
25. Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002; 359: 150-157 [PMID: 11809275 DOI: 10.1016/ S0140-6736(02)07374-9]
26. Broomé U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006; 26: 31-41 [PMID: 16496231 DOI: 10.1055/s-2006-933561]
27. Schrumpf E, Elgjo K, Fausa O, Gjone E, Kolmannskog F, Ritland S. Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol 1980; 15: 689-697 [PMID: 7209379 DOI: 10.3109/ 00365528009181516]
28. Lundqvist K, Broomé U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997; 40: 451-456 [PMID: 9106695 DOI: 10.1007/ BF02258391]
29. Kartheuser AH, Dozois RR, LaRusso NF, Wiesner RH, Ilstrup DM, Schleck CD. Comparison of surgical treatment of ulcerative colitis associated with primary sclerosing cholangitis: ileal pouch-anal anastomosis versus Brooke ileostomy. Mayo Clin Proc 1996; 71: 748-756 [PMID: 8691895]
30. Penna C, Dozois R, Tremaine W, Sandborn W, LaRusso N, Schleck C, Ilstrup D. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996; 38: 234-239 [PMID: 8801203 DOI: 10.1136/ gut.38.2.234]
31. Ståhlberg D, Veress B, Tribukait B, Broomé U. Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study. Dis Colon Rectum 2003; 46: 770-778 [PMID: 12794579 DOI: 10.1007/s10350-004-6655-5]
32. Wiesner RH, LaRusso NF, Dozois RR, Beaver SJ. Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. Gastroenterology 1986; 90: 316-322 [PMID: 2934290]
33. Rabinovitz M, Gavaler JS, Schade RR, Dindzans VJ, Chien MC, Van Thiel DH. Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects. Hepatology 1990; 11: 7-11 [PMID: 2295474 DOI: 10.1002/hep.1840110103]
34. Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol 2008; 14: 331-337 [PMID: 18200656 DOI: 10.3748/wjg.14.331]
35. Crohn BB, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci 1925; 170: 220-227 [DOI: 10.1097/00000441-192508010-00006]
36. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population- based study. Cancer 2001; 91: 854-862 [PMID: 11241255]
37. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535 [PMID: 11247898 DOI: 10.1136/gut.48.4.526]
38. Gillen CD, Andrews HA, Prior P, Allan RN. Crohn's disease and colorectal cancer. Gut 1994; 35: 651-655 [PMID: 8200559]
39. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population- based cohort studies. Clin Gastroenterol Hepatol 2012; 10: 639-645 [PMID: 22289873 DOI: 10.1016/j.cgh.2012.01.010]
40. Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C, Ullman T. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133: 1099-1105; quiz 1340-1341 [PMID: 17919486 DOI: 10.1053/ j.gastro.2007.08.001]
41. Jess T, Loftus EV, Velayos FS, Winther KV, Tremaine WJ, Zinsmeister AR, Scott Harmsen W, Langholz E, Binder V, Munkholm P, Sandborn WJ. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 2007; 102: 829-836 [PMID: 17222314 DOI: 10.1111/j.1572-0241.2007.01070.x]
42. Hendriksen C, Kreiner S, Binder V. Long term prognosis in ulcerative colitis--based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26: 158-163 [PMID: 3967834 DOI: 10.1136/gut.26.2.158]
43. Kewenter J, Ahlman H, Hultén L. Cancer risk in extensive ulcerative colitis. Ann Surg 1978; 188: 824-828 [PMID: 736660 DOI: 10.1097/00000658-197812000-00018]
44. Jess T, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012; 143: 375-381.e1; quiz e13-14 [PMID: 22522090 DOI: 10.1053/j.gastro.2012.04.016]
45. Broomé U, Lindberg G, Löfberg R. Primary sclerosing cholangitis in ulcerative colitis--a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 1992; 102: 1877-1880 [PMID: 1587406]
46. D'Haens GR, Lashner BA, Hanauer SB. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol 1993; 88: 1174-1178 [PMID: 8338083]
47. Broomé U, Löfberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 1404-1408 [PMID: 7590655]
48. Brentnall TA, Haggitt RC, Rabinovitch PS, Kimmey MB, Bronner MP, Levine DS, Kowdley KV, Stevens AC, Crispin DA, Emond M, Rubin CE. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996; 110: 331-338 [PMID: 8566577 DOI: 10.1053/gast.1996.v110.pm8566577]
49. Leidenius MH, Färkkilä MA, Kärkkäinen P, Taskinen EI, Kellokumpu IH, Höckerstedt KA. Colorectal dysplasia and carcinoma in patients with ulcerative colitis and primary sclerosing cholangitis. Scand J Gastroenterol 1997; 32: 706-711 [PMID: 9246712 DOI: 10.3109/00365529708996522]
50. Marchesa P, Lashner BA, Lavery IC, Milsom J, Hull TL, Strong SA, Church JM, Navarro G, Fazio VW. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997; 92: 1285-1288 [PMID: 9260790]
51. Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999; 94: 1643-1649 [PMID: 10364038 DOI: 10.1111/ j.1572-0241.1999.01156.x]
52. Loftus EV, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, Melton LJ. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology 1996; 110: 432-440 [PMID: 8566590 DOI: 10.1053/gast.1996.v110.pm8566590]
53. Nuako KW, Ahlquist DA, Sandborn WJ, Mahoney DW, Siems DM, Zinsmeister AR. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case-control study. Cancer 1998; 82: 822-826 [PMID: 9486569]
54. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56: 48-54 [PMID: 12085034 DOI: 10.1067/mge.2002.125367]
55. Brackmann S, Andersen SN, Aamodt G, Langmark F, Clausen OP, Aadland E, Fausa O, Rydning A, Vatn MH. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Scand J Gastroenterol 2009; 44: 46-55 [PMID: 18609187 DOI: 10.1080/00365520801977568]
56. Itzkowitz SH. Inflammatory bowel disease and cancer. Gastroenterol Clin North Am 1997; 26: 129-139 [PMID: 9119437 DOI: 10.1016/S0889-8553(05)70287-9]
57. Sandborn WJ. Inflammatory bowel disease and hereditary nonpolyposis colorectal cancer: is there a genetic link? Gastroenterology 1998; 114: 608-609 [PMID: 9496956 DOI: 10.1016/S0016-5085(98)70548-7]
58. Yin J, Harpaz N, Tong Y, Huang Y, Laurin J, Greenwald BD, Hontanosas M, Newkirk C, Meltzer SJ. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 1993; 104: 1633-1639 [PMID: 8500720]
59. Redston MS, Papadopoulos N, Caldas C, Kinzler KW, Kern SE. Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology 1995; 108: 383-392 [PMID: 7835579 DOI: 10.1016/0016-50 85(95)90064-0]
60. Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol 2008; 14: 378-389 [PMID: 18200660]
61. Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. Gut 2011; 60: 1739-1753 [PMID: 21300624 DOI: 10.1136/gut.2009.199679]
62. Muise AM, Walters TD, Glowacka WK, Griffiths AM, Ngan BY, Lan H, Xu W, Silverberg MS, Rotin D. Polymorphisms in E-cadherin (CDH1) result in a mis-localised cytoplasmic protein that is associated with Crohn's disease. Gut 2009; 58: 1121-1127 [PMID: 19398441 DOI: 10.1136/gut.2008.175117]
63. van Dieren JM, Wink JC, Vissers KJ, van Marion R, Hoogmans MM, Dinjens WN, Schouten WR, Tanke HJ, Szuhai K, Kuipers EJ, van der Woude CJ, van Dekken H. Chromosomal and microsatellite instability of adenocarcinomas and dysplastic lesions (DALM) in ulcerative colitis. Diagn Mol Pathol 2006; 15: 216-222 [PMID: 17122649 DOI: 10.1097/01. pdm.0000213470.92925.18]
64. Tahara T, Inoue N, Hisamatsu T, Kashiwagi K, Takaishi H, Kanai T, Watanabe M, Ishii H, Hibi T. Clinical significance of microsatellite instability in the inflamed mucosa for the prediction of colonic neoplasms in patients with ulcerative colitis. J Gastroenterol Hepatol 2005; 20: 710-715 [PMID: 15853983 DOI: 10.1111/j.1440-1746.2005.03803.x]
65. Pokorny RM, Hofmeister A, Galandiuk S, Dietz AB, Cohen ND, Neibergs HL. Crohn's disease and ulcerative colitis are associated with the DNA repair gene MLH1. Ann Surg 1997; 225: 718-723; discussion 723-725 [PMID: 9230812 DOI: 10.1097/00000658-199706000-00009]
66. Brentnall TA, Rubin CE, Crispin DA, Stevens A, Batchelor RH, Haggitt RC, Bronner MP, Evans JP, McCahill LE, Bilir N. A germline substitution in the human MSH2 gene is associated with high-grade dysplasia and cancer in ulcerative colitis. Gastroenterology 1995; 109: 151-155 [PMID: 7797014 DOI: 10.1016/0016-5085(95)90280-5]
67. Nagengast FM, Grubben MJ, van Munster IP. Role of bile acids in colorectal carcinogenesis. Eur J Cancer 1995; 31A: 1067-1070 [PMID: 7576993 DOI: 10.1016/0959-8049(95)00216-6]
68. Suzuki K, Bruce WR. Increase by deoxycholic acid of the colonic nuclear damage induced by known carcinogens in C57BL/6J mice. J Natl Cancer Inst 1986; 76: 1129-1132 [PMID: 3458949]
69. Ochsenkühn T, Bayerdörffer E, Meining A, Schinkel M, Thiede C, Nüssler V, Sackmann M, Hatz R, Neubauer A, Paumgartner G. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer 1999; 85: 1664-1669 [PMID: 10223558]
70. Bayerdörffer E, Mannes GA, Richter WO, Ochsenkühn T, Wiebecke B, Köpcke W, Paumgartner G. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 1993; 104: 145-151 [PMID: 8419237]
71. Qiao D, Chen W, Stratagoules ED, Martinez JD. Bile acidinduced activation of activator protein-1 requires both extracellular signal-regulated kinase and protein kinase C signaling. J Biol Chem 2000; 275: 15090-15098 [PMID: 10748108 DOI: 10.1074/jbc.M908890199]
72. Summerton J, Flynn M, Cooke T, Taylor I. Bile acid receptors in colorectal cancer. Br J Surg 1983; 70: 549-551 [PMID: 6311314 DOI: 10.1002/bjs.1800700914]
73. Hill MJ, Melville DM, Lennard-Jones JE, Neale K, Ritchie JK. Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis. Lancet 1987; 2: 185-186 [PMID: 2885641 DOI: 10.1016/ S0140-6736(87)90766-5]
74. Lashner BA, Heidenreich PA, Su GL, Kane SV, Hanauer SB. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology 1989; 97: 255-259 [PMID: 2568304]
75. Moody GA, Jayanthi V, Probert CS, Mac Kay H, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 1179-1183 [PMID: 8980937]
76. Biancone L, Michetti P, Travis S, Escher JC, Moser G, Forbes A, Hoffmann JC, Dignass A, Gionchetti P, Jantschek G, Kiesslich R, Kolacek S, Mitchell R, Panes J, Soderholm J, Vucelic B, Stange E. European evidence-based Consensus on the management of ulcerative colitis: Special situations. J Crohns Colitis 2008; 2: 63-92 [PMID: 21172196 DOI: 10.1016/ j.crohns.2007.12.001]
77. Farraye FA, Odze RD, Eaden J, Itzkowitz SH, McCabe RP, Dassopoulos T, Lewis JD, Ullman TA, James T, McLeod R, Burgart LJ, Allen J, Brill JV. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138: 738-745 [PMID: 20141808 DOI: 10.1053/j.gastro.2009.12.037]
78. Kitiyakara T, Chapman RW. Chemoprevention and screening in primary sclerosing cholangitis. Postgrad Med J 2008; 84: 228-237 [PMID: 18508979 DOI: 10.1136/pgmj.2007.064592]
79. Imam MH, Thackeray EW, Lindor KD. Colonic neoplasia in young patients with inflammatory bowel disease and primary sclerosing cholangitis. Colorectal Dis 2013; 15: 198-203 [PMID: 22712545 DOI: 10.1111/j.1463-1318.2012.03133.x]
80. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983; 14: 931-968 [PMID: 6629368 DOI: 10.1016/ S0046-8177(83)80175-0]
81. Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994; 107: 934-944 [PMID: 7926483]
82. Ullman TA, Loftus EV, Kakar S, Burgart LJ, Sandborn WJ, Tremaine WJ. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol 2002; 97: 922-927 [PMID: 12008669 DOI: 10.1111/j.1572-0241.2002.05610.x]
83. Befrits R, Ljung T, Jaramillo E, Rubio C. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum 2002; 45: 615-620 [PMID: 12004210 DOI: 10.1007/s10350-004-6255-4]
84. Lim CH, Dixon MF, Vail A, Forman D, Lynch DA, Axon AT. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 2003; 52: 1127-1132 [PMID: 12865270 DOI: 10.1136/gut.52.8.1127]
85. Zisman TL, Rubin DT. Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol 2008; 14: 2662-2669 [PMID: 18461651 DOI: 10.3748/wjg.14.2662]
86. Bernstein CN, Weinstein WM, Levine DS, Shanahan F. Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol 1995; 90: 2106-2114 [PMID: 8540497]
87. Eaden JA, Ward BA, Mayberry JF. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc 2000; 51: 123-128 [PMID: 10650251 DOI: 10.1016/S0016-5107(00)70405-6]
88. Hurlstone DP, Sanders DS, Lobo AJ, McAlindon ME, Cross SS. Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy 2005; 37: 1186-1192 [PMID: 16329015 DOI: 10.1055/s-2005-921032]
89. Kiesslich R, Hoffman A, Neurath MF. Colonoscopy, tumors, and inflammatory bowel disease - new diagnostic methods. Endoscopy 2006; 38: 5-10 [PMID: 16429347 DOI: 10.1055/ s-2005-921122]
90. Efthymiou M, Allen PB, Taylor AC, Desmond PV, Jayasakera C, De Cruz P, Kamm MA. Chromoendoscopy versus narrow band imaging for colonic surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 2132-2138 [PMID: 23899540 DOI: 10.1097/MIB.0b013e31829637b9]
91. Itzkowitz SH, Young E, Dubois D, Harpaz N, Bodian C, Chen A, Sachar DB. Sialosyl-Tn antigen is prevalent and precedes dysplasia in ulcerative colitis: a retrospective casecontrol study. Gastroenterology 1996; 110: 694-704 [PMID: 8608878 DOI: 10.1053/gast.1996.v110.pm8608878]
92. Greenwald BD, Harpaz N, Yin J, Huang Y, Tong Y, Brown VL, McDaniel T, Newkirk C, Resau JH, Meltzer SJ. Loss of heterozygosity affecting the p53, Rb, and mcc/apc tumor suppressor gene loci in dysplastic and cancerous ulcerative colitis. Cancer Res 1992; 52: 741-745 [PMID: 1346256]
93. Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994; 107: 117-120 [PMID: 7912678]
94. Martinez JD, Stratagoules ED, LaRue JM, Powell AA, Gause PR, Craven MT, Payne CM, Powell MB, Gerner EW, Earnest DL. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer 1998; 31: 111-118 [PMID: 9770722 DOI: 10.1080/01635589809514689]
95. Narisawa T, Fukaura Y, Terada K, Sekiguchi H. Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats. Jpn J Cancer Res 1998; 89: 1009-1013 [PMID: 9849578 DOI: 10.1111/j.1349-7006.1998. tb00489.x]
96. Earnest DL, Holubec H, Wali RK, Jolley CS, Bissonette M, Bhattacharyya AK, Roy H, Khare S, Brasitus TA. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res 1994; 54: 5071-5074 [PMID: 7923119]
97. Ikegami T, Matsuzaki Y, Shoda J, Kano M, Hirabayashi N, Tanaka N. The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett 1998; 134: 129-139 [PMID: 10025872 DOI: 10.1016/S0304-3835(98)00248-1]
98. Batta AK, Salen G, Holubec H, Brasitus TA, Alberts D, Earnest DL. Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps. Cancer Res 1998; 58: 1684-1687 [PMID: 9563483]
99. Wali RK, Frawley BP, Hartmann S, Roy HK, Khare S, Scaglione-Sewell BA, Earnest DL, Sitrin MD, Brasitus TA, Bissonnette M. Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-alpha, -beta II, and -zeta. Cancer Res 1995; 55: 5257-5264 [PMID: 7585585]
100. Im E, Martinez JD. Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J Nutr 2004; 134: 483-486 [PMID: 14747693]
101. Wali RK, Khare S, Tretiakova M, Cohen G, Nguyen L, Hart J, Wang J, Wen M, Ramaswamy A, Joseph L, Sitrin M, Brasitus T, Bissonnette M. Ursodeoxycholic acid and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin. Cancer Epidemiol Biomarkers Prev 2002; 11: 1653-1662 [PMID: 12496057]
102. Mitsuyoshi H, Nakashima T, Sumida Y, Yoh T, Nakajima Y, Ishikawa H, Inaba K, Sakamoto Y, Okanoue T, Kashima K. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun 1999; 263: 537-542 [PMID: 10491327 DOI: 10.1006/ bbrc.1999.1403]
103. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134: 89-95 [PMID: 11177311 DOI: 10.7326/0 003-4819-134-2-200101160-00008]
104. Pardi DS, Loftus EV, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-893 [PMID: 12671884 DOI: 10.1053/gast.2003.50156]
105. Wolf JM, Rybicki LA, Lashner BA. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005; 22: 783-788 [PMID: 16225486 DOI: 10.1111/j.1365-2036.2005.02650.x]
106. Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Lindor KD. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011; 106: 1638-1645 [PMID: 21556038 DOI: 10.1038/ajg.2011.156]
107. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336: 691-695 [PMID: 9041099 DOI: 10.1056/NEJM199703063361003]
108. Sinakos E, Marschall HU, Kowdley KV, Befeler A, Keach J, Lindor K. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. Hepatology 2010; 52: 197-203 [PMID: 20564380 DOI: 10.1002/hep.23631]
109. Debruyne PR, Bruyneel EA, Karaguni IM, Li X, Flatau G, Müller O, Zimber A, Gespach C, Mareel MM. Bile acids stimulate invasion and haptotaxis in human colorectal cancer cells through activation of multiple oncogenic signaling pathways. Oncogene 2002; 21: 6740-6750 [PMID: 12360401 DOI: 10.1038/sj.onc.1205729]
110. Baek MK, Park JS, Park JH, Kim MH, Kim HD, Bae WK, Chung IJ, Shin BA, Jung YD. Lithocholic acid upregulates uPAR and cell invasiveness via MAPK and AP-1 signaling in colon cancer cells. Cancer Lett 2010; 290: 123-128 [PMID: 19782465 DOI: 10.1016/j.canlet.2009.08.030]
111. McMillan L, Butcher S, Wallis Y, Neoptolemos JP, Lord JM. Bile acids reduce the apoptosis-inducing effects of sodium butyrate on human colon adenoma (AA/C1) cells: implications for colon carcinogenesis. Biochem Biophys Res Commun 2000; 273: 45-49 [PMID: 10873561 DOI: 10.1006/ bbrc.2000.2899]
112. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-678 [PMID: 20101749]
113. Singh S, Varayil JE, Loftus EV, Talwalkar JA. Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Transpl 2013; 19: 1361-1369 [PMID: 24019127]
114. Hansen JD, Kumar S, Lo WK, Poulsen DM, Halai UA, Tater KC. Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis. Dig Dis Sci 2013; 58: 3079-3087 [PMID: 23896754 DOI: 10.1007/s10620-013-2772-0]
115. Singh S, Khanna S, Pardi DS, Loftus EV, Talwalkar JA. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2013; 19: 1631-1638 [PMID: 23665966 DOI: 10.1097/MIB.0b013e318286fa61]